The consequence of oncomorphic TP53 mutations in ovarian cancer

Pavla Brachova, Kristina W. Thiel, Kimberly K. Leslie

Research output: Contribution to journalReview articlepeer-review

69 Scopus citations


Ovarian cancer is the most lethal gynecological malignancy, with an alarmingly poor prognosis attributed to late detection and chemoresistance. Initially, most tumors respond to chemotherapy but eventually relapse due to the development of drug resistance. Currently, there are no biological markers that can be used to predict patient response to chemotherapy. However, it is clear that mutations in the tumor suppressor gene TP53, which occur in 96% of serous ovarian tumors, alter the core molecular pathways involved in drug response. One subtype of TP53 mutations, widely termed gain-of-function (GOF) mutations, surprisingly converts this protein from a tumor suppressor to an oncogene. We term the resulting change an oncomorphism. In this review, we discuss particular TP53 mutations, including known oncomorphic properties of the resulting mutant p53 proteins. For example, several different oncomorphic mutations have been reported, but each mutation acts in a distinct manner and has a different effect on tumor progression and chemoresistance. An understanding of the pathological pathways altered by each mutation is necessary in order to design appropriate drug interventions for patients suffering from this deadly disease.

Original languageEnglish (US)
Pages (from-to)19257-19275
Number of pages19
JournalInternational journal of molecular sciences
Issue number9
StatePublished - Sep 23 2013


  • Chemoresistance
  • Mutant p53
  • Oncomorphic mutation
  • Ovarian cancer
  • TP53

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'The consequence of oncomorphic TP53 mutations in ovarian cancer'. Together they form a unique fingerprint.

Cite this